欢迎来到西安迈博睿(Mabioway)生物科技有限公司 Call: 15339069646 | E-mail: info@mabioway.cn 在线留言 |

服务热线

15339069646
网站导航
当前位置: 首页 > 产品展示 > 抗体产品 > 一抗 > 其他抗体
其他抗体
Anti-S1P mAbs [LT1009](MABL-6252)
  • Anti-S1P mAbs [LT1009](MABL-6252)

Anti-S1P mAbs [LT1009](MABL-6252)

简要描述:

For Research Use Only. Not for diagnostic or therapeutic use.

产品参数:

Cat. No.:MABL-6252

Application:crystallization, in vitro, in vivo, SPR, therapeutic, ELISA

Isotype:Engineer antibody

Species Reactivity:Human

Clone No.:LT1009

产品价格:¥0

详细介绍
Cat. No.
MABL-6252
Application
crystallization, in vitro, in vivo, SPR, therapeutic, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
LT1009
From
Recombinant Antibody
Specificity
The antibody binds S1P with high affinity and specificity. The interactions between the antibody and the antigen involve the Ca2+ and single oxygen atom from the phosphate head grup and the amino alchol region of S1P. The antibody does not cross reacts with structurally related lipids, including sphingosine (SPH). However, it does cross react with sphingosyl phosphocholine (SPC).
Alternative Names
Sonepcizumab; sphingosine‑1‑phosphate
UniProt
/
Immunogen
The original antibody was generated by grafting the CDR loops of the murine parent antibody (306D) onto a human IgG1K isotype framework. 306D was generated by immunizing mice with S1P.
Application Notes
The antibody blocked S1P‑mediated release of the pro‑angiogenic and prometastatic cytokine, interleukin‑8, from human ovarian carcinoma cells using an in vitro bioassay (\(IC50=374\)). The antibody demonstrated robust anti‑angiogenic activity in the choroidal neovascularization (CNV) model of age‑related macular degeneration (AMD) as well as disruption of lymphocyte trafficking when given intravenously (O'Brien et al., 2009; PMID: 19509417). The crystal structure of the Fab format of the antibody in complex with S1P was determined. The specificity of the IgG1 format of the antibody for S1P was confirmed by ELISA analysis. The Fab format of the antibody showed a binding affinity (KD) for S1P of 130 nM or 1.1 nM in the absence or presence of Ca2+ (Wojciak et al., 2009; PMID: 19815502). The original format of the antibody significantly reduced vascular leakage following laser rupture of bruch's membrane. The original format of the antibody was able to retard the progression of human colorectal (COLO0205) carcinoma tumors grafted subcutaneous (sc) and established in female Ncr (nu/nu) mice when used in combination with other anti‑cancer agents (Avastin 48% and Paclitaxel 100%). The original format of the antibody in combination with Avastin showed a tumor reduction of 41% of human HT29 colon tumor xenografts implanted sc in female athymic NCr‑nu/nu mice (US8067549B2).
Antibody First Published
O'Brien et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies J Lipid Res. 2009 Nov;50(11):2245-57. doi: 10.1194/jlr.M900048-JLR200. Epub 2009 Jun 9. PMID:19509417
Note on publication
The original paper describes the generation and characterization of the antibody.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.

 


服务咨询

留言框

  • 标题:

  • 留言内容:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 详细地址:

推荐产品

联系我们

Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有

地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层

电话:15339069646 邮箱:info@mabioway.cn

陕ICP备2021006339号